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PulmoScreen: A Novel Exhaled Breath Condensate Device.
 Craig Clements, Amie Wilkinson, Kavit Shah and Sterghios A. Moschos
Introduction
• Exhaled breath condensate (EBC) carries
abundant information on airway health and
disease, as well as systemic disease.1
• Current EBC samplers focus on volatile
compounds and protein biomarkers.
• This approach does not allow for analysis of
biomolecules (e.g. DNA, proteins,
metabolites).
• We are developing an optimised EBC
biomolecule sampler and analyser using
EBC microbiomics2 (infectious disease) as a
validation approach.
• This requires large EBC volume collection.3
• Cannot currently discriminate upper from
lower airway components (Fig. 1).
• Must eliminate environmental contamination.
• Must prevent sample loss.
Figure 1: Origin of biomarkers from the human airways. Although the 
airways are typically separated into upper and lower section, diseases 
affect specific sites across the respiratory tract. E.g. Tuberculosis affects 
immune cells of the alveolar sacs, asthma affects the bronchi and 
bronchioles and viral infections can affect various parts of the airways. 
Current EBC devices collect all exhaled air and are thus unable to select 
biomarker signals from specific airway regions. As a result, the disease-
relevant signal might be too diluted in a volume of irrelevant data arising 
from respiration.
Materials and Methods
• Total EBC was collected using a First
Generation device. Samples were then
removed from cartridge and returned to room
temperature.
• EBC volume was measured by pipetting (Fig. 2)
using a healthy adult 35 yo white male sampled
across 5 consecutive days.
• DNA extraction was performed using a liquid-
based bacteriolytic protocol and purification was
carried out using the Life Technologies Purelink
genomic DNA extraction kit.
• PCR amplification was carried out using the
KAPA Biosystems KAPA HiFi Polymerase and
primers for the V3 region of the 16S rRNA
gene5.
• Sequencing template was prepared using the
Ion Torrent One Touch and sequencing was
carried out using the Ion Torrent Personal
Genome Machine and 318 chip according to the
manufacturer’s instructions. Data was analysed
by QIIME according to RDP and plotted using
MEGAN5.
PulmoScreen Design, Volumetric 
& Microbiome  Data:
A research-grade airway biomarker collection 
device for laboratory-based testing:
• Simple components for in-lab assembly or kit
commercialization (Fig. 3).
• Compact design for community / field use.
• Compatible with all analytic technologies for volatile
and biological compounds.
• Leverages >20 years of pharmaceutical technology
development to provide airway compartmentalization
solutions (2nd generation).
• Consistent sample collection performance (Fig. 2).
• Efficient detection of airway microbiome in EBC
using standardised phylogenetic methods (Fig. 4).
PulmoScreen Design & 
Improvements:
Progress to commercialisation:
• Rapid prototype device successfully produced.
• Prototype tested to demonstrate sample sealing
and isolation from environmental contamination
(Fig. 5).
• Patent awarded6 and patent pending in
preparation for commercial production.
• 3rd generation device development under way.
Conclusions
• Pulmoscreen is an efficient system for EBC
sample collection and laboratory based sample
analysis.
• Our technology enables EBC segregation across
airway compartments.
• Analytical technique high sensitivity permits
microbiomic analyses in as little as a single breath.
• General improvements have projected the project
into the next design phase that will include several
autonomous, modular, and non-invasive
modifications such as:


Integrated T control and sensor circuitry. 
On-the-fly sample extraction technology.
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Figure 5. Liquid immersion tests demonstrate sampler isolation from 
environmental contamination. Ingress of liquids (A) causes bubble formation, 
indicating sample contamination risk. Appropriate modification of components (B 
and C) ensure complete isolation between the collector and lid (A), mouthpiece 
assembly (B) and system housing (C).
Figure 2: Sample collection performance. Single operator me (A, D) and EBC 
volume collection (B, C) metrics across a range of sample collection temperatures. 
Reproducibility across 3-5 breaths is shown, with performance at optimal temperature 
range depicted in (C) and (D). Data relevant to single airway compartment only, 
obtained across 5 consecutive days in a controlled environment using a single subject.
Figure 3: Pulmoscreen designs. The first generation device (A) is a total EBC 
collection system engineered to isolate EBC from environmental contamination and 
prevent salivary contamination through inertial impaction (red surface). A retractable 
drawer arrangement (B) facilitates sample isolation preventing both sample loss 
and environmental contamination. The second generation device (B) utilises the 
same sample isolation principle in cascade impactor array format to enable 
sample separation by particle size. A single impaction stage drawer assembly is shown, 
with the lid retracted. The lid is supplied in an isolated housing to ensure EBC collection 
stage isolation after sampling. This opens up uses for segmented airway bioanalysis 
as well as non-invasive inhaled pharmaceutical deposition metrics.
Figure 4: Detection of airway microbiome by 16S next 
generation sequencing using the first generation instrument. (A) PCR 
amplification of the V3 variable region of the microbial ribosomal RNA gene 
increases according to EBC sample size (total no. of breaths analysed). A 198 bp 
amplicon denotes detection of bacteria. No amplicon was detected in either 
PCR reaction control or filtered-air condensates, indicating signal arises 
from the airway microbiome. (B) Phylogenetic analysis of airway microbial 
population resembles observations with invasive techniques suggesting a 
dominance of alveolar microbiome signal.4 Sequencing was carried out using a 
318 chip on the Ion Torrent Personal Genome Machine; chip loading 
efficiency (C), read quality (D) and read length (E) metrics are shown. 
Comparison of four independent EBC microbiome signatures (EBC A-D) to paired 
salivary microbiome samples (SAL A-D) demonstrates distinct microbial populations 
in the two loci. Rarefaction analysis confirms adequate microbial population 
sampling (G).
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